tbuckley/cabot-search huggingface dataset:
HAWAIIAN FEVER.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Obstructing peptic ulcers
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
APRIL modulates B and T cell immunity
Authors: Jens V. Stein, Marta López-Fraga, Fernando A. Elustondo, Carla E. Carvalho-Pinto, Dolores Rodríguez, Ruth Gómez-Caro, Joan de Jong, Carlos Martínez-A, Jan Paul Medema, Michael Hahne
Journal: Journal of Clinical Investigation (2002)

The TNF-like ligands APRIL and BLyS are close relatives and share the capacity to bind the receptors TACI and BCMA. BLyS has been shown to play an important role in B cell homeostasis and autoimmunity, but the biological role of APRIL remains less well defined. Analysis of T cells revealed an activation-dependent increase in APRIL mRNA expression. We therefore generated mice expressing APRIL as a transgene in T cells. These mice appeared normal and showed no signs of B cell hyperplasia. Transgenic T cells revealed a greatly enhanced survival in vitro as well as enhanced survival of staphylococcal enterotoxin B–reactive CD4+ T cells in vivo, which both directly correlate with elevated Bcl-2 levels. Analysis of humoral responses to T cell–dependent antigens in the transgenic mice indicated that APRIL affects only IgM but not IgG responses. In contrast, T cell–independent type 2 (TI-2) humoral response was enhanced in APRIL transgenic mice. As TACI was previously reported to be indispensable for TI-2 antibody formation, these results suggest a role for APRIL/TACI interactions in the generation of this response. Taken together, our data indicate that APRIL is involved in the induction and/or maintenance of T and B cell responses.
Status epilepticus
Authors: C. F. Nicol
Journal: JAMA (1975)

STATUS epilepticus rarely occurs as the initial manifestation of an idiopathic epileptic disorder or in a patient whose seizures have been effectively controlled for a long time. Far too often, it follows the sudden cessation of maintenance therapy; there is no justification, therefore, for stopping medication before obtaining an electroencephalogram. Other causes of status epilepticus include infection, which is not necessarily confined to the central nervous system, occlusive cerebral vascular disease, metabolic and hypertensive encephalopathies, primary and secondary brain tumors, head trauma, degenerative central nervous system diseases of obscure origin, and, rarely, systemic diseases including the collagen diseases. Diagnosis of the type of status epilepticus is usually made by history and by observation of at least one seizure. Because the patient loses consciousness in major motor epilepsy, the testimony of a competent witness is necessary. In focal motor epilepsy, the patient may remain conscious during a seizure and is thus
肠道微生物群失调
Authors: C. Hidalgo‐Cantabrana, J. Gómez, S. Delgado, S. Requena‐López, R. Queiro‐Silva, A. Margolles, E. Coto, B. Sánchez, P. Coto‐Segura
Journal: British Journal of Dermatology (2019)

人类和其他动物的皮肤和肠道中生存着由不同细菌组成的复杂混合体(称为微生物群), 这些微生物在帮助我们保持健康方面发挥着重要的作用。 在若干疾病状态中发现了不同细菌病例的变化;将此称为失调。健康肠道中不同细菌的混合体在形成和维持健康免疫系统过程中扮演重要的角色。尽管已知银屑病患者皮肤上的微生物群相比健康个体发生了变化,关于他们肠道中不同细菌的比例知之甚少。 在西班牙若干不同部门工作的作者们表示,肠道微生物群的变化在银屑病发生中可能发挥一定作用。他们通过从新鲜粪便样本中提取细菌 DNA 比较了居住在相同地区的 19 名银屑病患者和 20 名健康对照者(无银屑病的人)的肠道微生物群。 作者们发现,银屑病患者样本的细菌多样性降低,一些在健康对照者中不存在的细菌菌种相对丰富。这表明需要进一步研究比较不同严重程度银屑病患者和不同模式银屑病患者中微生物群的模式。 这可能有助于确立肠道失调是否在此病发生中发挥作用;如果是,旨在改变肠道细菌组成的治疗可能会有一席之地,如粪便细菌移植或使用益生菌治疗。
Do patients participating in oncology clinical trials understand the informed consent form? A Brown University Oncology Research Group study—BrUOG 274.
Authors: Andrew Schumacher, Howard Safran, Carolyn Bartley, Brittany Cammisa, Alise Lombardo, Cynthia Leach, Denise Luppe, Rachael Rossiter, Kayla Rosati
Journal: Journal of Clinical Oncology (2015)

e17702 Background: Clinical trials are becoming increasingly complex with advancing research, which subsequently leads to longer, more complicated consent forms. Patient understanding is an essential part to obtaining an ethically valid consent. The purpose of this trial is to evaluate patient’s understanding of the informed consent document when participating in oncology clinical trials. Methods: Patients receiving active treatment on a cooperative group, pharmaceutical industry or investigator initiated clinical trial were administered a 14-question survey. The survey was developed to evaluate their understanding of the basic elements of the informed consent process including purpose and procedures, risks, benefits, potential alternatives, research related injury compensation, study contact information, confidentiality, and voluntary nature. Possible answers to each question were: Disagree, Unsure, and Agree. Results: This study started June 2012 and completed October 2014; 54 patients were entered and 50 were assessable. Patient characteristics included Caucasian (88%), English as 1st language (96%); 52% had at least an Associates Degree. The average length of the consent forms were 15.9 pages with an 11.1 reading grade level. Among misconceptions identified included: 1) 90% of patients thought all treatments and procedures were standard of care for their cancer, 2) 86% thought that the treatment being given in the study had been proven to be the best for their cancer, and 3) 20% thought that the study did not have any additional risks or discomforts. > 80% of patients taking the survey held these misconceptions. All patients knew they were taking part in a treatment study and 98% knew that participation was voluntary in that study. Additionally 90% knew that the main reason to for the treatment study was to improve treatment for future cancer patients. Conclusions: The results show that patients do not fully comprehend the consent form and the required information needs to be presented in a manner that patients can follow and understand easily. Assessment of comprehension of the simplified NCI consent form is planned in an upcoming trial. Clinical trial information: NCT01772511.
Prognostic Value of Positron Emission Tomography- Computed Tomography in Patients with Marginal Zone Lymphoma
Authors: Ji Hyun Park, Dok Hyun Yoon, Sun Mok Kim, Jae-Cheol Jo, Jeongseok Kim, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Sang-wook Lee, Chan-Sik Park, Jooryung Huh, Cheolwon Suh
Journal: Blood (2012)
Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis
Authors: Amalia Gastaldelli, Melania Gaggini, Michael Allison, Ramy Younes, Chiara Rosso, Jörn M. Schattenberg, Vlad Ratziu, Elisabetta Bugianesi, Quentin Anstee
Journal: Journal of Hepatology (2020)
Annales Medicine Internae Fenniae, Helsinki
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Determination of heparin‐induced thrombocytopenia: A rapid flow cytometric assay for direct demonstration of antibody‐mediated platelet activation
Authors: Aaron Tomer, Cynthia Masalunga, Thomas C. Abshire
Journal: American Journal of Hematology (1999)

Heparin-induced thrombocytopenia (HIT) and thrombosis are serious complications of heparin therapy. Recently, we have reported a practical and rapid functional flow cytometric assay (FCA) for the diagnosis of HIT with high specificity and sensitivity compared with the radioactive serotonin-release assay (SRA). In the present study, we added an immune-neutralization assay to directly demonstrate the antibody-mediated process, and tested the immune compatibility of low-molecular-weight heparin (LMWH) Lovenox and the heparinoid Orgaran (danaproid) using plasma from 18 patients with HIT confirmed by both FCA and SRA. The clinical utility of this modified method is demonstrated by a pediatric patient with a complex clinical presentation who developed thrombocytopenia with multiple thromboses while on heparin therapy. ELISA and SRA (performed in three independent laboratories) for diagnosis of HIT were both negative. In contrast, the FCA for detecting activated platelets expressing anionic phospholipids, was highly and reproducibly positive with both unfractionated and LMWH. Another FCA also demonstrated the surface expression of the α-granule membrane p-selectin (CD62p). Compatibility testing with the heparinoid Orgaran was also positive (and with plasma from 4 of the 18 patients with HIT). Heparin was discontinued, along with full recovery of the platelet count. The capacity of the patient's plasma to activate platelets in the presence of heparin gradually decreased over 4 weeks consistent with antibody clearance. The responsible mechanism was clarified using an immune-neutralization assay, which showed a dose response neutralization of the plasma activity by antibodies against human Immunoglobulin G (IgG) and IgM. This assay was also reproducible in the 18 patients with HIT. We conclude that the functional FCA with its modification is practical, sensitive, and specific for reliable diagnosis of HIT. It can simultaneously assess the compatibility of alternative therapies and directly confirm the antibody-mediated process. Further, it is particularly useful to clarify mechanisms of thrombocytopenia and thrombosis and to direct therapy in patients with a complex presentation and confounding laboratory results who often need prompt diagnosis and treatment. Am. J. Hematol. 61:53–61, 1999. © 1999 Wiley-Liss, Inc.
Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Results of Fol-Brite
Authors: Frederick Lansigan, Bassem I Zaki, Stephanie P Yen, Eric S Winer, Helen Ryan, Darcie L Findley, Sara R Metzler, Lynn Shaw, Annie Tsui, Todd MacKenzie, Anne W Beaven
Journal: Blood (2014)
6-Mercaptopurine—Its Effects on Transplants Are 'Far From Uniform'
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Addiction
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1826: MALAT1 regulates EGFR translation by KTN1-mediated transcriptomic change in cutaneous squamous cell carcinoma
Authors: Lin Gao, Liang Zhou, Shanshan Li, Zhenhua Ding, Junying Qiu, Malin Hong, Chang Zou
Journal: Cancer Research (2019)

Abstract Introduction MALAT1 is a member of lncRNAs that has been implicated in breast, cervical, colorectal cancers. However, its role in cutaneous squamous cell carcinoma (cSCC) is not clear. In this study, functional studies using in vitro and in vivo confirmed MALAT1 promotes tumor growth, migration and invasiveness of cSCC. MALAT1 regulates EGFR protein expression but not in RNA level. It shows that identified KTN1 as the key mediator for MALAT1 regulation of EGFR. Methods Total RNAs from cells were extracted using TRIzol for qRT-PCR. Cells were transfected with MALAT1 ASOs or siKTN1_1, siKTN1_2 and cell proliferation were detected using a cell counting kit as described in the manual. Cells were seeded into chambers for transwell assay. Visible cells were photographed and counted after stained for cell migration and invasiveness assays. Total cell or cSCC tissues were prepared and assayed by western blot as previously described. Bound antibodies were visualised using the Luminated Forte Western HRP substrate. For histochemistry staining, 10 μm tissue sections were fixed for 10min with 4% paraformaldehyde, and then incubated with antibodies. The pictures of stained IHC sections were taken under Leica Fluorescence Microscope. Statistical data were presented as mean values ± stand deviation and considered to reflect significant differences. Results Our results revealed that MALAT1 was markedly higher expressed in A431, HSC-1 and HSC-5 cSCC cells than in HaCaT keratinocytes. MALAT1 exhibited much higher expression in cSCC primary tumors compared to normal tissues. In addition, KTN1 and EGFR protein were higher expression in cSCC tissues. Significant loss of MALAT1 repressed proliferation, migration, and invasiveness but promoted apoptosis of cSCC cells. Loss of MALAT1 led to the significant downregulation of KTN1 through RNA sequencing assay accompanied with lower EGFR protein expression. However, knockdown of KTN1 had effect on the protein expression of EGFR but no effect on RNA levels. The results implied that MALAT1 may regulate EGFR protein expression through inducing KTN1 mRNA transcription. Conclusions In this study, we revealed a novel mechanism of cSCC treatment, MALAT1 can transcriptionally activates KTN1, positively regulates EGFR protein expression in cSCC. It may provide a new series of drug target for anti-cSCC therapy. Citation Format: Lin Gao, Liang Zhou, Shanshan Li, Zhenhua Ding, Junying Qiu, Malin Hong, Chang Zou. MALAT1 regulates EGFR translation by KTN1-mediated transcriptomic change in cutaneous squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1826.
Organic: What's in a Name?
Authors: Brandy E. Fisher
Journal: Environmental Health Perspectives (1999)

The organic foods industry is booming: by one estimate, the market for organic foods is worth $4 billion annually and is expected to grow at a rate of more than 24% per year. Faced with the threat of pesticide exposures and other food safety problems, many consumers are turning to organic foods in hopes of finding a healthy alternative, but there is currently no consistency in organic food labeling and no guarantee that foods labeled as organic are actually grown and processed in a purely organic fashion. There is also controversy about whether the label "organic" covers such new technologies as irradiation and genetic engineering. As part of the 1990 Farm Bill, the U.S. Department of Agriculture (USDA) is working to develop a proposed rule on organic foods. The rule would regulate the allowable methods, practices, and substances used in producing and handling crops and their processed products. The first draft of the proposed rule, released in December 1997, met with unprecedented opposition, which centered around the fact that the proposal appeared to virtually ignore the recommendations of a standards board formed to assist in the rule's development. Other criticism opposed three practices put forward for comment by the USDA: irradiation, genetic engineering, and the use of sewage sludge in farming. Due to the vehemence of the opposition to its original proposal, the USDA has decided to rewrite the proposed rule. In preparation for that proposal, the USDA Agricultural Marketing Service released three issue papers in October 1998 for public comment. The 10,000-plus comments received in response to those papers will be incorporated into the second draft proposal, due out later this year.
Black Esophagus
Authors: S Dogan, F Omurca, N Yagan, T Purnak
Journal: Endoscopy (2021)

A 60-year-old woman presented to the emergency clinic because of cough and dyspne. She reported black, tarry stool from the rectum during hospitalization. Upper endoscopy revealed that edematous, swollen mucosa in the esophagus with scattered ulcers and white exudates, as well as black discoloration. Multiple biopsies were obtained, pathologic evaluation was compatible with extensive necrosis. Endoscopic findings were also suggestive for acute esophageal necrosis. ın other words, black esophagus, characterised by diffusely swollen, edematous, black esopageal mucosa with patchy ulcers and confined to the Z-line. Black esophagus is considered secondary to tissue hypoperfusion, ischemia and acid injury in most cases.
Hypertension.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LONDON
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal